IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.
To explore the mechanism of immunosuppression associated with sepsis, we developed a murine model of sepsis-induced Pseudomonas aeruginosa pneumonia. CD-1 mice underwent either cecal ligation and 26-gauge needle puncture (CLP) or sham surgery, followed by the intratracheal (i.t.) administration of P. aeruginosa or saline. Survival in mice undergoing CLP followed 24 h later by the i.t. administration of saline or P. aeruginosa was 58% and 10%, respectively, whereas 95% of animals undergoing sham surgery followed by P. aeruginosa administration survived. Increased mortality in the CLP/P. aeruginosa group was attributable to markedly impaired lung bacterial clearance and the early development of P. aeruginosa bacteremia. The i.t. administration of bacteria to CLP-, but not sham-, operated mice resulted in an impressive intrapulmonary accumulation of neutrophils. Furthermore, P. aeruginosa challenge in septic mice resulted in a relative shift toward enhanced lung IL-10 production concomitant with a trend toward decreased IL-12. The i.p., but not i.t., administration of IL-10 Abs given just before P. aeruginosa challenge in septic mice significantly improved both survival and clearance of bacteria from the lungs of septic animals administered P. aeruginosa. Finally, alveolar macrophages isolated from animals undergoing CLP displayed a marked impairment in the ability to ingest and kill P. aeruginosa ex vivo, and this defect was partially reversed by the in vivo neutralization of IL-10. Collectively, these observations indicate that the septic response substantially impairs lung innate immunity to P. aeruginosa, and this effect is mediated primarily by endogenously produced IL-10.
Steinhauser
M L
ML
Department of Medicine, University of Michigan Medical School, Ann Arbor 48109-0360, USA.
Hogaboam
C M
CM
Kunkel
S L
SL
Lukacs
N W
NW
Strieter
R M
RM
Standiford
T J
TJ
D000005:Abdomen; D000818:Animals; D002432:Cecum / Q000601:surgery; D002465:Cell Movement / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D005260:Female; D007106:Immune Sera / Q000008:administration & dosage; D007113:Immunity, Innate; D007274:Injections, Intraperitoneal; D016753:Interleukin-10 / Q000276:immunology / Q000502:physiology*; D007442:Intubation, Intratracheal; D008026:Ligation; D008168:Lung / Q000276:immunology* / Q000382:microbiology*; D051379:Mice; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis / Q000276:immunology; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D011552:Pseudomonas Infections / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D011550:Pseudomonas aeruginosa / Q000276:immunology / Q000302:isolation & purification; D011677:Punctures; D018746:Systemic Inflammatory Response Syndrome / Q000276:immunology* / Q000382:microbiology / Q000401:mortality
D016207:Cytokines; D007106:Immune Sera; D016753:Interleukin-10